SAN FRANCISCO (Thomson Financial) - Celgene Corp.'s Celgene International
Sarl unit said Friday that data showed its Vidaza drug provides a "significant
overall survival benefit" for patients with higher-risk myelodysplastic
syndromes.
Vidaza was compared with low-dose Ara-C in the United Kingdom and France,
and compared with best supportive care in Germany, Italy, Sweden, Greece, Spain
and the Netherlands, Celgene said.
In May 2004, Vidaza was approved in the United States by for the treatment
of patients with myelodysplastic syndromes.
"These data reinforce Vidaza's role and the importance of this epigenetic
drug in the treatment paradigm for higher-risk MDS patients," said Valeria
Santini, lead investigator of the trial, in a statement. "These results continue
to show that Vidaza can provide a significant overall survival benefit
regardless of which regimen is used for comparison."
The data was presented at the 13th Congress of the European Hematology
Association in Copenhagen, Denmark.
Shares of Summit, N.J.-based Celgene were up $1.13, or 1.9%, at $59.88.
Katherine Hunt
kh
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|